3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other neoplasm
1
Gastrointestinal
1
Conditions
Prostatic Neoplasms
2
Breast Neoplasms
2
Vascular Diseases
1
Rectal Neoplasms
1
Precancerous Conditions
1
Neurotoxicity Syndromes
1
Myocardial Ischemia
1
Myocardial Infarction
1
Heart Diseases
1
Fibrosis
1
Fatigue
1
Erectile Dysfunction
1
Coronary Disease
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Cerebrovascular Disorders
1
Cardiovascular Diseases
1
Brain Neoplasms
1
Adenomatous Polyps
1
Interventions
Oxaliplatin
49
Fluorouracil
45
Leucovorin
42
Capecitabine
40
Irinotecan
31
Bevacizumab
31
Radiotherapy
24
Cetuximab
23
Radiation
13
Panitumumab
13
Folfox protocol
10
Surgical Procedures, Operative
9
IFL protocol
8
Radiotherapy, Intensity-Modulated
6
Magnetic Resonance Spectroscopy
6
aflibercept
5
Immunohistochemistry
5
Gene Expression Profiling
5
Chemotherapy, Adjuvant
5
Fluorodeoxyglucose F18
4
Floxuridine
4
Celecoxib
4
trifluridine tipiracil drug combination
3
dehydroftorafur
3
XELOX
3
Sorafenib
3
Ramucirumab
3
Neoadjuvant Therapy
3
Erlotinib Hydrochloride
3
Drug Therapy
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Rectal Neoplasms
×
Vitamin E
×
Clear all
NCT00706121
2019-12-16
ACP
SWOG Cancer Research Network
Phase 3
Completed
8,094 enrolled
23 charts